Selank (10mg)

Description

What is Selank?

Selank (Thr‑Lys‑Pro‑Arg‑Pro‑Gly‑Pro) is a synthetic heptapeptide developed at the same Russian Academy of Sciences institute that developed Semax. It is based on the endogenous immunomodulatory tetrapeptide tuftsin (with a C‑terminal Pro‑Gly‑Pro extension for enzymatic stability). It is registered in Russia for generalized anxiety disorder and studied for immune and cognitive effects.

Mechanism of Action

• Modulates GABAergic and serotonergic neurotransmission without direct benzodiazepine‑receptor binding
• Alters expression of brain BDNF and NGF in rodent models
• Increases enkephalin enzymatic stability, extending endogenous opioid peptide signaling
• Immunomodulatory effects inherited from the tuftsin parent sequence

Compound Properties

• Molecular formula: C₃₃H₅₇N₁₁O₉
• Molecular weight: ~751.88 g/mol
• Sequence: Thr‑Lys‑Pro‑Arg‑Pro‑Gly‑Pro (TKPRPGP)
• Form: Lyophilized powder
• Unit size: 10 mg / vial
• Source: Solid‑phase peptide synthesis; ≥98% purity by HPLC

Research‑Reference Dosing

Published research‑reference ranges:

• Zozulia et al., Zhurnal Nevrologii i Psikhiatrii (2008): Selank in generalized anxiety disorder vs. medazepam comparator.
• Medvedev et al., Neuroscience and Behavioral Physiology: preclinical anxiolytic and cognitive data.
• Kolik et al.: rodent anxiolytic and antidepressant‑like behavioral paradigms.
• Like Semax, Western peer‑reviewed clinical evidence is limited.

Research Findings

• Anxiolytic efficacy comparable to low‑dose benzodiazepines in Russian GAD cohorts without sedation or dependence signals (Zozulia 2008)
• Immunomodulatory effects on leukocyte activity in preclinical models
• Preclinical cognitive enhancement and antidepressant‑like activity

Known Side Effects Reported in Research/Trials

• Generally well tolerated
• Rare mild headache, somnolence, or nasal irritation (intranasal dosing)
• No benzodiazepine‑like sedation or withdrawal reported in published cohorts
• Long‑term safety data outside Russian clinical registries is limited

Storage & Handling

• Lyophilized (unreconstituted) vials: store at −20°C long‑term; short‑term 2–8°C acceptable.
• After reconstitution with bacteriostatic or sterile water: store at 2–8°C; use within 14–28 days per standard peptide stability guidance.
• Protect from light, heat, and repeated freeze‑thaw cycles. Handle in a sterile laboratory environment.

Certificate of Analysis

A Certificate of Analysis (COA) confirming identity and purity by HPLC / MS is available upon request. Contact Lonestar Peptides for lot‑specific documentation.

Summaries reference peer‑reviewed preclinical and clinical literature available as of early 2025. Newer findings may not be reflected. Researchers should consult current literature and conduct their own due diligence. Lonestar Peptides makes no claim of therapeutic benefit.